Madelynn Whittaker
@mnwhittaker.bsky.social
boston-based scientist editing DNA and occasionally her coffee order
Reposted by Madelynn Whittaker
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. www.wired.com/story/crispr...
Crispr Pioneer Launches Startup to Make Tailored Gene-Editing Treatments
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases.
www.wired.com
January 9, 2026 at 11:06 AM
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. www.wired.com/story/crispr...
Reposted by Madelynn Whittaker
Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The @fda.gov outlines a path to market entry for products where a randomized trial is not feasible. Learn more: nej.md/4nUQdcl
November 12, 2025 at 10:40 PM
Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The @fda.gov outlines a path to market entry for products where a randomized trial is not feasible. Learn more: nej.md/4nUQdcl
Reposted by Madelynn Whittaker
My first-author paper was published today in Nature Biomedical Engineering! Here we describe how incorporating DNA substitutions into various positions of the Cas9 guide RNA protospacer can enhance the precision and performance of adenine base editors. 🧬 ✂️
October 28, 2025 at 7:36 PM
My first-author paper was published today in Nature Biomedical Engineering! Here we describe how incorporating DNA substitutions into various positions of the Cas9 guide RNA protospacer can enhance the precision and performance of adenine base editors. 🧬 ✂️
Reposted by Madelynn Whittaker
🧬Proud to share "Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs" my 1st first-author paper of my PhD, co-first-authored with the brilliant Dr. @mnwhittaker.bsky.social, is out today in Nature Biomedical Engineering! www.nature.com/articles/s41...
Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs - Nature Biomedical Engineering
Hybrid gRNAs significantly increase targeted editing in the liver while simultaneously reducing unwanted bystander editing in humanized mouse models.
www.nature.com
October 28, 2025 at 12:58 PM
🧬Proud to share "Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs" my 1st first-author paper of my PhD, co-first-authored with the brilliant Dr. @mnwhittaker.bsky.social, is out today in Nature Biomedical Engineering! www.nature.com/articles/s41...
Reposted by Madelynn Whittaker
Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable go.nature.com/4kCD1Y3
July 16, 2025 at 12:02 PM
Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable go.nature.com/4kCD1Y3